Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 56fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 32Cyclosporine 32Filgrastim 31Busulfan 31Mycophenolic Acid 30Antilymphocyte Serum 28Radiotherapy 27Whole-Body Irradiation 25Melphalan 23Tacrolimus 18Methylprednisolone 18Cord Blood Stem Cell Transplantation 17Methotrexate 16Etoposide 16Cytarabine 9Thiotepa 8sargramostim 6fludarabine 6aldesleukin 6Sirolimus 6Rituximab 6thymoglobulin 5Therapeutics 5Psychiatric Rehabilitation 5Granulocyte Colony-Stimulating Factor 5Doxorubicin 4Vincristine 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Triamcinolone × Sarcoma × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡